Search
Phathom Pharmaceuticals Inc
PHATAdd to Watchlist
5.250USD
+0.170+3.35%
Close 11-05 16:00（ET）
426.77MMarket Cap
LossP/E TTM
Today
+3.35%
5 Days
-15.59%
1 Month
-21.64%
6 Months
-58.32%
Year to Date
-68.35%
1 Year
-60.47%
Key Figures
5.260Open
5.705High
240.54KVolume
LossP/E TTM
6.30P/E Dynamic
--Dividend TTM
0.30%Turnover Ratio
5.080Prev. Close
5.040Low
1.24MTurnover
LossP/E Static
-1.22P/B
0.00%Div Yield TTM
-52.49%ROA
18.31052wk High
0.10Volume Ratio
-334.33MNet Profit
81.29MShares
-2.0938EPS TTM
0.53Beta
-3489.00%ROE
5.01552wk Low
13.09%Amplitude
78.32%Gross Margin
426.77MMarket Cap
-2.71Reward/Risk
4.23%Risk Rate
Phathom Pharmaceuticals Inc's Score
-0.27vs previous score
Forecast8.33
Financial Health6.99
Technical5.08
Valuation Dimensions8.95
Institutional Confidence7.00
Risk Assessment4.34
Media Coverage
Coverage Level
Very Low
Very High
Positive+
Analyst Rating
Phathom Pharmaceuticals Inc Technical Analysis
Technical Indicators
Sell
Summary
Sell
Moving Average
Strong sell
Phathom Pharmaceuticals Inc Latest Earnings Call Transcripts
Phathom Pharmaceuticals (PHAT) Q3 2026 Earnings Call: Revenue Rises 71%, Guidance Reaffirmed
Phathom Pharmaceuticals’ Q3 2026 earnings call covered $84.7 million in revenue, positive operating profit, VOQUEZNA growth and reaffirmed guidance.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-0.16/-0.14
Revenue / Forecast
84.72M/85.18M
Phathom Pharmaceuticals Inc Profile
SectorPharmaceuticals
Ticker SymbolPHAT
Number of employees427
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Frazier Life Sciences Management, L.P. | 15.63% |
| Medicxi Ventures (UK) LLP | 9.36% |
| Millennium Management LLC | 5.24% |
| Abingworth Management Limited | 4.38% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 22.16% |
| Venture Capital | 19.25% |
| Private Equity | 16.16% |
| Investment Advisor/Hedge Fund | 12.43% |
Related Instruments
-0.79%
+1.43%
+1.07%
-0.14%
+0.38%
-0.22%
+0.03%
-0.41%
+0.02%
-0.20%
+0.85%
-1.57%
-1.04%
+0.28%
+5.27%
-0.16%
+0.16%
-0.80%
+1.46%
+3.63%Popular Instruments
51290.600
-208.500 (-0.41%)
26964.500
+329.300 (+1.24%)
7380.000
+23.100 (+0.31%)
12797.000
-1.000 (-0.01%)
58142.000
+876.000 (+1.53%)
6140.600
-37.200 (-0.60%)
89.857
-0.176 (-0.20%)
342.370
-1.800 (-0.52%)
186.640
+5.040 (+2.78%)
4065.670
-33.020 (-0.81%)
FAQs
What is the current price of Phathom Pharmaceuticals Inc (PHAT)?
The current price of Phathom Pharmaceuticals Inc (PHAT) is 5.08.
What is the symbol of Phathom Pharmaceuticals Inc?
The ticker symbol of Phathom Pharmaceuticals Inc is PHAT.
What is the 52-week high of Phathom Pharmaceuticals Inc?
The 52-week high of Phathom Pharmaceuticals Inc is 18.31.
What is the 52-week low of Phathom Pharmaceuticals Inc?
The 52-week low of Phathom Pharmaceuticals Inc is 5.01.
What is the market capitalization of Phathom Pharmaceuticals Inc?
The market capitalization of Phathom Pharmaceuticals Inc is 412.95M.
Is Phathom Pharmaceuticals Inc (PHAT) currently rated as Buy, Hold, or Sell?
According to analysts, Phathom Pharmaceuticals Inc (PHAT) has an overall rating of Buy, with a price target of 20.05.
What is the Earnings Per Share (EPS TTM) of Phathom Pharmaceuticals Inc (PHAT)?
The Earnings Per Share (EPS TTM) of Phathom Pharmaceuticals Inc (PHAT) is -2.09.